Stockreport

How EMBOLD Efficacy Stop And Ulixacaltamide FDA Pathway At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story [Yahoo! Finance]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF Praxis Precision Medicines reported that its EMBOLD trial of relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies was stopped early for efficacy, [Read more]